Nanjing Sanhome Pharmaceutical, Co., Ltd.

This early-stage study tests a new drug called SH006, given in combination with other treatments, for people with advanced solid tumors (including liver cancer) who have not responded to standard therapy. The main goals are to check safety, find the best dose, and see if the drug…

This early-stage study tests a new oral drug (SH3765) combined with fulvestrant in 30 women with HR-positive, HER2-negative advanced breast cancer that has worsened after prior hormone therapy. The main goals are to find a safe dose and check for side effects, while also measurin…